Finance

Beta
Lists
ORKA:NASDAQ
Oruka Therapeutics Inc
$95.17
+2.90%
(+2.68) 1D
$97.00
+1.92% (+1.83)
After hours
Closed: Jun 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORKA...
Open
$92.50
High
$97.78
Low
$90.26
Mkt. cap
5.74B
Avg. vol.
1.53M
Volume
1.76M
52-wk high
$97.78
52-wk low
$10.97
EPS
-$2.39
Beta
-0.29
Shares outstanding
60.31M
No. of employees
68
Open
$92.50
High
$97.78
Low
$90.26
Mkt. cap
5.74B
Avg. vol.
1.53M
Volume
1.76M
52-wk high
$97.78
52-wk low
$10.97
EPS
-$2.39
Beta
-0.29
Shares outstanding
60.31M
No. of employees
68
News stories
From sources across the web
About Oruka Therapeutics Inc
CEO-
Employees68
Founded2024
HeadquartersWestminster, Colorado, United States
SectorBiotechnology
Analyst ratings
Based on 12 analysts giving stock ratings to ORKA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ORKA in the last 3 months.
Highest
Current $95.17
$200.00 (+110.15%)
Average
$148.20 (+55.72%)
Lowest
$100.00 (+5.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$150.00
+57.6%
06/29/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$120.00
+26.1%
06/23/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$180.00
+89.1%
06/02/2026
Michael Yee
UBS
Buy
Reiterated
$100.00
+5.1%
06/02/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$125.00
+31.3%
05/23/2026
David Nierengarten
Wedbush
Buy
Maintained
$165.00
+73.4%
05/14/2026
Julian Harrison
BTIG
Buy
Maintained
$151.00
+58.7%
05/13/2026
Etzer Darout
Barclays
Buy
Reiterated
$160.00
+68.1%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/13/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$131.00
+37.6%
04/27/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$200.00
+110.2%
04/27/2026
Martin Fan
Wedbush
Buy
Maintained
$85.00
-10.7%
04/15/2026
Roger Song
Jefferies
Buy
Maintained
$45.00
-52.7%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.09M
28.99M
27.64M
29.14M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.34M
5.12M
6.79M
7.29M
Operating expense
28.43M
34.10M
34.43M
36.43M
Total operating expenses
28.43M
34.10M
34.43M
36.43M
Operating income
-28.43M
-34.10M
-34.43M
-36.43M
Other non operating income
-2.00K
-4.00K
-1.00K
8.00K
EBT including unusual items
-24.57M
-30.28M
-29.58M
-31.82M
EBT excluding unusual items
-24.57M
-30.28M
-29.58M
-31.82M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-24.57M
-30.28M
-29.58M
-31.82M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.55
-0.45
-0.48
Interest and investment income
3.86M
3.83M
4.85M
4.61M
Interest expense
-
-
-
-
Net interest expenses
3.86M
3.83M
4.85M
4.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.41M
-34.08M
-34.40M
-36.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more